VWA
DFTX

Visionary Wealth Advisors’s Definium Therapeutics DFTX Stock Holding History

Visionary Wealth Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-700
Closed -$24K – 391
2021
Q3 		$24K Buy
+700
New +$30.3K ﹤0.01% 311

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Visionary Wealth Advisors's DFTX Position: Q4 2021 in Review

Visionary Wealth Advisors sold out of Definium Therapeutics (DFTX) in Q4 2021, closing a stake of 700 shares — an estimated $24K sold.

Visionary Wealth Advisors first reported a position in DFTX in Q3 2021 and held it in 1 quarter. The position peaked at $24K in Q3 2021. 176 funds tracked by Wall St. Rank hold DFTX as of Q4 2021.

  • Visionary Wealth Advisors reported no remaining Definium Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Visionary Wealth Advisors sold 700 Definium Therapeutics shares in Q4 2021, an estimated $24K.
  • Visionary Wealth Advisors first reported a position in Definium Therapeutics in Q3 2021 and held it in 1 quarter.
  • Visionary Wealth Advisors's Definium Therapeutics position peaked at $24K in Q3 2021.
  • 176 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2021.

Based on Visionary Wealth Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.